Oncology

Jun 12, 2026

Pfizer's USD 10.5 billion partnership with Innovent Biologics is not just another oncology deal; it is a strategic masterstroke in Pfizer's bid to dominate cancer therapy. In May 2026, Pfizer and Innovent announced a global collaboration covering 12 early-stage and de novo oncology programs, including next-generati...

May 21, 2025

Artificial Intelligence (AI), with its wide range of applications, is enhancing the speed and accuracy of businesses across various industries, including manufacturing, healthcare, finance, marketing, and many others. To take advantage, globally, companies, whether big or small, are actively adopting artificial int...

Nov 29, 2024

Non-small cell lung cancer (NSCLC) is the most common cancer, accounting for approximately 85% of all lung cancers. the total number of incident cases of NSCLC across the 7MM was approximately 500,000 in 2022 and is projected to reach around 600,000 cases by 2032. Studies show that non-small cell lung cancer aff...

Nov 01, 2024

A Neuroendocrine tumor is a type of cancer where neuroendocrine cells develop into tumors. Whereas Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) are tumors that arise from neuroendocrine cells in the gut. A Neuroendocrine Tumor grows slowly and aggressively and tends to spread to other parts of the body. ...

Dec 18, 2023

The development of complement inhibitors has been growing rapidly over the years, and it has proved to be one of the breakthroughs in various therapeutic areas. These inhibitors act on the dysregulated complement system, a group of proteins that forms an essential part of innate immunity. This system comes into eff...

Dec 15, 2023

Date of Abstract presentation12th December 2023IndicationsMantle Cell Lymphoma (MCL)Abstract NumberLBA-2Abstract typeOral Ibrutinib, an oral BTK inhibitor, holds approval in numerous countries for the treatment of R/R MCL. Similarly, venetoclax, an oral BCL2 inhibitor, has gained approval in multiple countries f...

Dec 15, 2023

Date of Abstract presentation11th December 2023IndicationsRelapsed or Refractory (R/R) B-Cell MalignanciesAbstract Number4401Abstract typePoster The preliminary results from this ongoing clinical trial, unveiled at the ASH 2023 conference, demonstrated that, among the efficacy evaluable patients (n=28), BGB-1667...

Dec 14, 2023

Date of Abstract presentation11th December 2023IndicationsMultiple MyelomaAbstract Number1014Abstract typeOral TALVEY (talquetamab) is a bispecific T-cell engaging antibody designed to target the CD3 receptor found on T-cells and G protein-coupled receptor class C group 5 member D (GPRC5D). The findings presente...

Dec 14, 2023

Date of Abstract presentation12th December 2023IndicationsAcute LeukemiaAbstract NumberLBA-5Abstract typePoster According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia within the KMT2Ar cohorts. Among them...

Nov 27, 2023

The FDA has approved label extensions for two of the most crucial cancer medications globally—Merck’s Keytruda and Pfizer and Astellas’ Xtandi. Keytruda’s expanded indication now includes stomach cancer, permitting its usage alongside chemotherapy for first-line treatment in patients with locally advanced unresecta...